Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from AIM ImmunoTech ( (AIM) ) is now available.
AIM ImmunoTech announced that Thomas K. Equels and Peter W. Rodino III have decided to forego their entitled cash bonuses for 2024. This decision aims to allocate more financial resources towards the company’s Ampligen research and development activities, reflecting a strategic move to prioritize long-term growth and innovation over immediate compensation.
More about AIM ImmunoTech
YTD Price Performance: -56.72%
Average Trading Volume: 448,657
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $12.12M
Find detailed analytics on AIM stock on TipRanks’ Stock Analysis page.